医薬品リファレンス
Etuvetidigene autotemcel
Etuvetidigene autotemcel is a medicine in the class miscellaneous.
- 薬効分類: Miscellaneous
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Miscellaneous
- 一般的な剤形
- 注射剤
- 商品名
- 1
- 国・市場
- 1
作用のしくみ
Adds full-length copies of the human WAS cDNA into the patient's hematopoietic stem cells by lentiviral vector transduction. After infusion the modified cells engraft in bone marrow and repopulate the hematopoietic compartment, and their progeny express WAS protein (WASP).
成人の通常用量（添付文書の要約）
Wiskott-Aldrich Syndrome: minimum recommended dose 7 × 10 6 CD34 + cells/kg based on body weight at infusion, single-dose intravenous infusion via central venous catheter; maximum volume must remain < 20% of estimated plasma volume
妊娠と授乳
- 妊娠
- Unsafe One-time gene therapy (own modified stem cells). No data in pregnancy. It must not be given during pregnancy because of the risks of the conditioning chemotherapy. Confirm a negative pregnancy test first; use contraception from stem-cell collection until at least 6 months after the infusion.
- 授乳
- Unsafe No data on presence in milk. Nearly all patients are boys (X-linked disease). Because of the risks of conditioning chemotherapy, breastfeeding must stop during conditioning; afterwards follow the advice for the conditioning drugs.
報告されている副作用
- Catheter related infection
- Bacterial and viral infections
- Diarrhea
- Vomiting
- Stomatitis
- Liver injury
禁忌
- Hypersensitivity to the active substance or to any of the excipients
- Previous HSCT within 6 months prior to treatment, or HSCT with evidence of residual donor cells
- Previous treatment with hematopoietic stem cell gene therapy
注意が必要な方
- Hypersensitivity and infusion-related reactions, including anaphylaxis, may occur due to DMSO; monitor during and after infusion
- Engraftment failure may occur; if so, infuse non-transduced back-up stem cells
- Severe cytopenias occur for several weeks; monitor for at least 8 weeks
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Etuvetidigene autotemcelの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- How to give it
- Patient counselling points
- IV preparation and dilution
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Etuvetidigene autotemcel used for?
Etuvetidigene autotemcel is a medicine in the class miscellaneous.
What side effects have been reported with Etuvetidigene autotemcel?
Catheter related infection, Bacterial and viral infections, Diarrhea, Vomiting, Stomatitis, Liver injury.
Can Etuvetidigene autotemcel be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. One-time gene therapy (own modified stem cells). No data in pregnancy. It must not be given during pregnancy because of the risks of the conditioning chemotherapy. Confirm a negative pregnancy test first; use contraception from stem-cell collection until at least 6 months after the infusion. Breastfeeding: Unsafe. No data on presence in milk. Nearly all patients are boys (X-linked disease). Because of the risks of conditioning chemotherapy, breastfeeding must stop during conditioning; afterwards follow the advice for the conditioning drugs.
What does Etuvetidigene autotemcel interact with?
MediHelp does not list a checked interaction for Etuvetidigene autotemcel yet. Always tell your pharmacist about every medicine you take.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
